FDA Deliberates on an Emerging Type 2 Diabetes Drug Class

Before you go, we thought you'd like these...
Before you go close icon

With the PDUFA date for Johnson & Johnson's SGLT-2 inhibitor Invokana just around the corner, the FDA will soon deliberate on another Type 2 diabetes drug that belongs to the same class: Eli Lilly's empagliflozin. Can these drugs get the green light, or will the FDA require both companies to run more clinical trials? Is the FDA's rejection of Forxiga, an SGLT-2 inhibitor developed by Bristol-Myers Squibb  and AstraZeneca a signal that these drugs will face an uphill battle during the approval process? Health-care analyst Max Macaluso discusses these topics in the following video.

Is Eli Lilly a buy or sell?
With two of its top three drugs poised to lose patent protection this year, is Eli Lilly a dividend stock headed nowhere fast? In a new premium report, The Motley Fool's senior pharmaceuticals analyst breaks down all of Lilly's moving parts, including an in-depth analysis of the company's must-know opportunities and reasons to buy and sell today. To find out more, click here to claim your copy today.

The article FDA Deliberates on an Emerging Type 2 Diabetes Drug Class originally appeared on Fool.com.

Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool recommends and  owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners